GlassScriptPhysician profile
David T Pearce
NPI 1033573985
$5,131.80
in general payments reported to CMS, 2019-2025
20 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $315 · 2021: $937 · 2022: $1,127 · 2023: $848 · 2024: $904 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,164.04 | 2019-2025 | |
| Abbvie INC. | $938.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $756.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $430.65 | 2020-2025 | Zerbaxa, Dificid, Verquvo |
| Janssen Pharmaceuticals, INC | $400.09 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.21 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $254.11 | 2021-2024 | Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.92 | 2020-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $148.78 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $133.80 | 2020-2023 | Andexxa |
| Paratek Pharmaceuticals, INC. | $96.09 | 2022-2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $73.64 | 2019-2023 | Ultomiris |
| Novo Nordisk INC | $60.14 | 2019-2024 | Rybelsus |
| Boston Scientific Corporation | $56.32 | 2020-2022 | |
| Sk Life Science, INC. | $38.01 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $29.72 | 2022 | |
| Abbott Laboratories | $24.94 | 2024 | Mitraclip |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
| Electromed, INC. | $14.59 | 2023 | Smartvest |
| Shire North American Group INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.